Publications by authors named "Jacques Hamon"

16Publications

Multidimensional de novo design reveals 5-HT2B receptor-selective ligands.

Authors:
Tiago Rodrigues Nadine Hauser Daniel Reker Michael Reutlinger Tiffany Wunderlin Jacques Hamon Guido Koch Gisbert Schneider

Angew Chem Int Ed Engl 2015 Jan 4;54(5):1551-5. Epub 2014 Dec 4.

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Vladimir-Prelog-Weg 4, 8093 Zurich (Switzerland).

View Article and Find Full Text PDF
January 2015

Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes.

Authors:
Anne Mai Wassermann Peter S Kutchukian Eugen Lounkine Tiffany Luethi Jacques Hamon Michael T Bocker Hasnain A Malik Sandra W Cowan-Jacob Meir Glick

J Med Chem 2013 Nov 31;56(21):8879-91. Epub 2013 Oct 31.

Novartis Institutes for Biomedical Research Inc. , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

View Article and Find Full Text PDF
November 2013

Identification of the C3a receptor (C3AR1) as the target of the VGF-derived peptide TLQP-21 in rodent cells.

Authors:
Sebastien Hannedouche Valerie Beck Juliet Leighton-Davies Martin Beibel Guglielmo Roma Edward J Oakeley Vincent Lannoy Jerome Bernard Jacques Hamon Samuel Barbieri Inga Preuss Marie-Christine Lasbennes Andreas W Sailer Thomas Suply Klaus Seuwen Christian N Parker Frederic Bassilana

J Biol Chem 2013 Sep 12;288(38):27434-43. Epub 2013 Aug 12.

From Novartis AG, Novartis Campus, CH-4056 Basel, Switzerland and.

View Article and Find Full Text PDF
September 2013

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Authors:
Pascal Furet Vito Guagnano Robin A Fairhurst Patricia Imbach-Weese Ian Bruce Mark Knapp Christine Fritsch Francesca Blasco Joachim Blanz Reiner Aichholz Jacques Hamon Doriano Fabbro Giorgio Caravatti

Bioorg Med Chem Lett 2013 Jul 14;23(13):3741-8. Epub 2013 May 14.

Novartis Institutes for BioMedical Research, WKL-136.4.12, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2013

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:
Joanne Bowes Andrew J Brown Jacques Hamon Wolfgang Jarolimek Arun Sridhar Gareth Waldron Steven Whitebread

Nat Rev Drug Discov 2012 Dec;11(12):909-22

AstraZeneca R&D, Alderley Park, Cheshire SK10 4TG, UK.

View Article and Find Full Text PDF
December 2012

Large-scale prediction and testing of drug activity on side-effect targets.

Authors:
Eugen Lounkine Michael J Keiser Steven Whitebread Dmitri Mikhailov Jacques Hamon Jeremy L Jenkins Paul Lavan Eckhard Weber Allison K Doak Serge Côté Brian K Shoichet Laszlo Urban

Nature 2012 Jun 10;486(7403):361-7. Epub 2012 Jun 10.

Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.

View Article and Find Full Text PDF
June 2012

In vitro safety pharmacology profiling: what else beyond hERG?

Authors:
Jacques Hamon Steven Whitebread Valerie Techer-Etienne Helene Le Coq Kamal Azzaoui Laszlo Urban

Future Med Chem 2009 Jul;1(4):645-65

Center for Proteomic Chemistry, Novartis Pharma AG, Forum 1, 4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2009

Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis.

Authors:
Josef Scheiber Bin Chen Mariusz Milik Sai Chetan K Sukuru Andreas Bender Dmitri Mikhailov Steven Whitebread Jacques Hamon Kamal Azzaoui Laszlo Urban Meir Glick John W Davies Jeremy L Jenkins

J Chem Inf Model 2009 Feb;49(2):308-17

Lead Discovery Informatics and Preclinical Safety Profiling, CPC, Novartis Institutes for Biomedical Research, 250 Massachussetts Avenue, Cambridge, Massachusetts 02139, USA.

View Article and Find Full Text PDF
February 2009

Mapping adverse drug reactions in chemical space.

Authors:
Josef Scheiber Jeremy L Jenkins Sai Chetan K Sukuru Andreas Bender Dmitri Mikhailov Mariusz Milik Kamal Azzaoui Steven Whitebread Jacques Hamon Laszlo Urban Meir Glick John W Davies

J Med Chem 2009 May;52(9):3103-7

Lead Discovery Informatics, CPC, Novartis Institutes for Biomedical Research, 250 Massachussetts Avenue, Cambridge, Massachusetts 02139, USA.

View Article and Find Full Text PDF
May 2009

Modeling promiscuity based on in vitro safety pharmacology profiling data.

Authors:
Kamal Azzaoui Jacques Hamon Bernard Faller Steven Whitebread Edgar Jacoby Andreas Bender Jeremy L Jenkins Laszlo Urban

ChemMedChem 2007 Jun;2(6):874-80

CPC/LFP/MLI, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Postfach, 4002 Basel, Switzerland.

View Article and Find Full Text PDF
June 2007

Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.

Authors:
Andreas Bender Josef Scheiber Meir Glick John W Davies Kamal Azzaoui Jacques Hamon Laszlo Urban Steven Whitebread Jeremy L Jenkins

ChemMedChem 2007 Jun;2(6):861-73

Lead Finding Platform, Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Ave., Cambridge, Massachusetts 02139, USA.

View Article and Find Full Text PDF
June 2007

Clustering and rule-based classifications of chemical structures evaluated in the biological activity space.

Authors:
Ansgar Schuffenhauer Nathan Brown Peter Ertl Jeremy L Jenkins Paul Selzer Jacques Hamon

J Chem Inf Model 2007 Mar-Apr;47(2):325-36. Epub 2007 Feb 8.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
May 2007

High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.

Authors:
Bernard Faller Jianling Wang Alfred Zimmerlin Leslie Bell Jacques Hamon Steven Whitebread Kamal Azzaoui Dejan Bojanic Laszlo Urban

Expert Opin Drug Metab Toxicol 2006 Dec;2(6):823-33

Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
December 2006

Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects.

Authors:
Stefan Raduner Adriana Majewska Jian-Zhong Chen Xiang-Qun Xie Jacques Hamon Bernard Faller Karl-Heinz Altmann Jürg Gertsch

J Biol Chem 2006 May 17;281(20):14192-206. Epub 2006 Mar 17.

Department of Chemistry and Applied Biosciences, ETH Zurich, Wolfgang-Pauli-Strasse 10, CH-8093 Zürich, Switzerland.

View Article and Find Full Text PDF
May 2006

Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.

Authors:
Steven Whitebread Jacques Hamon Dejan Bojanic Laszlo Urban

Drug Discov Today 2005 Nov;10(21):1421-33

PreClinical Profiling, Lead Discovery Center, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

View Article and Find Full Text PDF
November 2005

Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.

Authors:
Anne-Claude Dublanchet Pierre Ducrot Charles Andrianjara Margaret O'Gara Renaud Morales Delphine Compère Alexis Denis Stéphane Blais Philippe Cluzeau Karine Courté Jacques Hamon François Moreau Marie-Laure Prunet Anita Tertre

Bioorg Med Chem Lett 2005 Aug;15(16):3787-90

Department of Chemistry, Pfizer Global Research and Development, Fresnes Laboratories, 3-9 rue de la Loge, BP 100, F-94265 Fresnes Cedex, France.

View Article and Find Full Text PDF
August 2005